Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial
25/06/2026 12:23
BRIEF-Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial June 25 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O:
NATERA AND ELEDON ANNOUNCE STRATEGIC PARTNERSHIP FOR PROSPERA™ MONITORING IN PLANNED PHASE 3 KIDNEY TRANSPLANT TRIAL
NATERA AND ELEDON ANNOUNCE STRATEGIC PARTNERSHIP FOR PROSPERA™ MONITORING IN PLANNED PHASE 3 KIDNEY TRANSPLANT TRIAL
NATERA - ELEDON TO INITIATE PHASE 3 KIDNEY TRANSPLANT TRIAL IN LATE 2026
Source text: ID:nBw3wq2pNa
Further company coverage: ELDN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers